

Ortivus communicates a growth target of 15% annually

Ortivus' goal is to reach an organic growth of an average of 15% annually while maintaining profitability, to achieve at least 25 MSEK profit within 4 years. Ortivus aims to increase sales to existing customers, gain additional market shares and reach new geographical markets in the prehospital and primary care segment.

Ortivus has built a strong market position facilitating assessments, record keeping and data sharing in prehospital care. MobiMed is currently used by over 12,000 paramedics and in more than 2,700 emergency vehicles. MobiMed is today installed in 45% of Sweden's ambulances and in 25% of the ambulances in the UK. Ortivus also support Singapore's entire mobile emergency care, with approximately 1,300 MobiMed users. In primary care, that is a new segment for Ortivus, has a customised version of MobiMed been installed in several Swedish regions during 2021.

Ortivus has in-house sales and service organisations in the Nordics as well as in the UK. MobiMed are however, delivered to Italy and Singapore through our local partners. Ortivus has in the recent years developed a well-functioning strategic partnership model where the company, in collaboration with locally established partners, can access and grow into new geographical markets. Strategic partnerships have recently been established in Australia, New Zealand, and Eastern Europe. This strategy makes it possible to handle large customer installations remotely, enabling a cost-effective growth.

Ortivus' offering consists of the MobiMed platform that can be divided into three different product groups:

- MobiMed Monitor, that in real time measures, monitors and shares ECG and vital signs such as blood pressure and oxygenation,
- MobiMed ePR, an electronic patient record for clinical documentation and advanced decision support, and
- MobiMed Life, a portfolio of stand-alone defibrillators.

With a weight of only 3.5 kg, MobiMed is created for optimal ergonomics and a demanding work out in the field. Through two-way communication, it is possible to consult medical experts at a distance, while clinical documentation and patient data are seamlessly integrated into the hospital records. For three decades, Ortivus has supplied reliable equipment for prehospital and cardiac care. The company continues to develop innovative and user-friendly solutions in close collaboration with nurses and medical doctors.

Market Conditions

The fast development of communication technology and cloud-based services makes it possible for a secure and efficient management of digital patient data. The digitization of patient information, such as medical history, current medication, and allergies, is made possible through electronic record keeping. The transition from record keeping using paper and pen to electronic Press Release 21 April 2022 08:30:00 CEST



records with advanced decision support, facilitates assessments and improves treatment outcomes. The quality of care is thereby enhanced while the efficiency is increased as real time patient information can be shared between different connected systems. In parallel, new mobile medical technology solutions are being developed to be used remotely to facilitate a patientcentered care.

The care need increases at the same rate as the growing and aging population and there is a demand to move healthcare closer to the patient. This is made possible by rapid technological improvements. The European primary care market, including home care, is expected to grow by 8% annually over the next five years^{*}. A lot of focus will be on developing remote care, for example through mobile care teams. The prehospital care will also have to focus more on out of hospital care and the European market for remote monitoring is expected to grow by 14% annually until 2027^{**}. Public healthcare funds will be directed more towards a patient-centered care - supported by digital solutions.

*Source: <u>https://www.grandviewresearch.com/industry-analysis/europe-home-care-market</u> ** Source: <u>https://www.marketdataforecast.com/market-reports/europe-remote-patient-monitoring-</u> market

Contacts

For further information, please contact

Reidar Gårdebäck, CEO

Telefon +46 8 446 45 00



About Ortivus

Ortivus develops and commercialises MobiMed, medical technology solutions for a safer and more efficient

healthcare. The company was founded in 1985 and is today a leading provider of mobile digital solutions for prehospital care, worldwide. Ortivus' products are based on in-depth expertise in cardiology as well as decades of development together with users and customers. The company's headquarters are located in Danderyd, Stockholm and the company has, since 1998, a wholly-owned subsidiary based in the United Kingdom.

MobiMed is a modular platform that currently is used by over 12,000 paramedics in over 2,700 emergency vechicles. The platform consists of a monitor that in real-time measures, monitors and shares patients'

vital parameters, such as, ECG, blood pressure and blood oxygenation. The system also consists of an electronic patient record for decision support, collection of patient data and clinical documentation.

MobiMed has a total weight of 3.5kg and is created to function in a demanding environment and out in

the field. The two-way communication supports telemedicine consulting with clinical experts while patient data is seamlessly integrated into the medical records at the hospitals and primary care centers. MobiMed saves time and helps healthcare professionals make the right decisions in critical situations. MobiMed also contributes to improved quality of care and saved resources.

Ortivus Class A and Class B shares are listed on the NASDAQ Stockholm Small Cap list.

Read more about Ortivus at www.ortivus.com

This information is information that Ortivus is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 2022-04-21 08:30 CEST.

Attachments

Ortivus communicates a growth target of 15% annually